Using MicroRNAs to Improve Neuromodulation Study Quantification

Abstract

In recent years, neuromodulation has been gaining popularity as a potential therapy method for various ailments, including acute heart failure (AHF). There are currently five clinical trials using neuromodulation techniques to improve hemodynamics among patients with AHF. However, these studies can be limited by their outcome measurement methods as they utilize variables such as C-Reactive protein levels (CRP), or blood pressure (BP), and adverse events that can be easily confounded. Thus, we propose that micro-RNAs (miRNAs) have great potential to be reliable biomarkers that would significantly enhance outcome measurements of these studies as changing levels of various miRNAs are correlated with many different aspects of AHF.